Testing a diabetes drug for nonobstructive hypertrophic cardiomyopathy
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a common diabetes drug (SGLT2 inhibitor) to see if it helps people with nonobstructive hypertrophic cardiomyopathy (HCM). The medicine may improve how your heart works and how well you can exercise.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have nonobstructive HCM with symptoms or limited exercise ability
- You have been on stable heart medications for at least 1 month
- Your heart’s pumping strength (ejection fraction) is above 50%
- You do not have type 1 diabetes or advanced kidney disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a drug can help suppress sugar uptake in the heart for clearer imaging. It may help researchers understand how to better see heart problems.
This trial studies whether two medicines—an SGLT2 inhibitor and potassium nitrate—can improve symptoms and heart function in people with heart failure with preserved ejection fraction (HFpEF). It focuses on people who still have signs of “stiff” or high filling pressure in the heart despite a normal-ish ejection fraction.
This trial compares a new study drug (BHB-1893) with a standard heart medication called metoprolol to see which one better improves symptoms in people with obstructive hypertrophic cardiomyopathy. If you join, you will be randomly assigned to receive either the study drug or metoprolol, and your symptoms and heart function will be monitored over time.
This study tests whether a diabetes drug (empagliflozin) can improve the heart's ability to relax and fill with blood in people with non-obstructive hypertrophic cardiomyopathy, a type of heart muscle thickening. You may be able to join if you have this condition and are not currently taking an SGLT2 inhibitor.
This trial tests a new medicine, henagliflozin, to see if it can reduce scarring (fibrosis) in the heart muscle of people with non-obstructive hypertrophic cardiomyopathy. The goal is to improve heart health and slow down disease progression.
This trial tests whether a diabetes medication, called an SGLT2 inhibitor, can reduce inflammation around heart arteries in people who have had a heart attack but do not have diabetes. The study uses a special heart scan to look at changes over time.
Hear when a new Hypertrophic Cardiomyopathy Without Obstruction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.